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OXA-48-producing isolates were identiﬁed in approximately 4% and less than 1% of ESBL-producing and
non-ESBL-producing E. coli and K. pneumoniae causing bacteremia at the largest tertiary hospital in Abu
Dhabi.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idCarbapenems offer an important treatment option for infec-
tions caused by Enterobacteriaceae, in particular those producing
extended-spectrum b-lactamase (ESBL). However, several classes
of carbapenemases have emerged with the increased use of
carbapenems. In the United Arab Emirates (UAE), the antimicrobial
resistance rates of Escherichia coli and Klebsiella pneumoniae
increased signiﬁcantly between 1994 and 2006.1 In terms of
carbapenem resistance, detection of Enterobacteriaceae isolates
producing NDM, and less frequently OXA-48, have been reported
in the UAE.2–4
In the present study, we sought to systematically identify
carbapenemase-producing E. coli and K. pneumoniae causing
bacteremia at the largest tertiary medical center in Abu Dhabi,
UAE. E. coli and K. pneumoniae clinical isolates identiﬁed from
blood cultures were collected between 2011 and 2012. Only one
isolate was collected per patient. A total of 80 ESBL-producing and
150 non-ESBL-producing isolates were collected, as determined by
Vitek2 (bioMe´rieux, Marcy l’Etoile, France). The isolates were then
screened for carbapenem non-susceptibility by growth on Luria-
Bertani agar plates containing 0.5 mg/ml of ertapenem. As a result,* Corresponding author. Division of Infectious Diseases, Department of Medicine,
University of Pittsburgh Medical Center, S829 Scaife Hall, 3550 Terrace Street,
Pittsburgh, PA 15261. Tel.: +12-648-9445; fax: +412-648-8521.
E-mail address: yod4@pitt.edu (Y. Doi).
http://dx.doi.org/10.1016/j.ijid.2014.11.008
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).4 isolates (1 ESBL-producing E. coli, 2 ESBL-producing K.
pneumoniae and 1 non-ESBL-producing K. pneumoniae) were
conﬁrmed to have reduced susceptibility to ertapenem and
studied further. The 4 isolates were tested for the presence of
blaSHV, blaCTX-M, blaKPC, blaNDM and blaOXA-48 genes by PCR
ampliﬁcation followed by conﬁrmation with DNA sequencing.
Minimum inhibitory concentrations (MICs) of various antimicro-
bial agents were determined by the broth microdilution method
(Sensititre GNX2F, Thermo Scientiﬁc, Cleveland, OH) and inter-
preted according to the Clinical Laboratory Standards (CLSI)
breakpoints. MICs of meropenem were determined with Etest
(bioMe´rieux). Multilocus sequence typing (MLST) was performed
according to published protocols (http://www.pasteur.fr/
recherche/genopole/PF8/mlst/Kpneumoniae.html and http://
mlst.warwick.ac.uk/mlst). De-identiﬁed medical records of the
bacteremia cases were reviewed for demographic and clinical data.
The study was approved by the Institutional Review Board of
Sheikh Khalifa Medical City, Abu Dhabi.
All 4 patients with ertapenem-non-susceptible Enterobacter-
iaceae had healthcare-associated bacteremia (1 with E. coli and
3 with K. pneumoniae) (Table 1). Two were in an intensive care unit
and on mechanical ventilation at the time of bacteremia. The
APACHE II scores were high, ranging between 15 and 29. All
patients were Arabic natives, but two of them had traveled
overseas within 3 months prior to bacteremia (Saudi Arabia and
the United Kingdom). All patients were treated with meropenemciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Bacteremia cases due to OXA-48-producing Enterobacterieaceae in Abu Dhabi, UAE.
Case (Isolate) Age Sex Ethnicity Travel
history
Admitting
diagnosis
Underlying conditions Therapy
given
Meropenem
MIC (mg/ml)
Survival at
14 days
ST Concomitant
ESBLs
1 (E. coli 12) 60s Male Arabic Not
recorded
Sepsis Cirrhosis, diabetes CTX then
MEM
0.38 Deceased 4144 CTX-M-14,
SHV-12
2 (K.
pneumoniae
70)
70s Female Arabic Saudi
Arabia
Spinal
fracture
Cardiovascular
disease, diabetes
MEM 0.25 Survived 340 CTX-M-15
3 (K.
pneumoniae
c80)
50s Female Arabic United
Kingdom
Malignancy Metastatic gastric
cancer
TZP then
MEM + CST
0.5 Survived 1425 SHV-12
4 (K.
pneumoniae
c82)
 20 Female Arabic None Malignancy Acute lymphoblatic
leukemia, neutropenia
MEM 0.38 Survived 29 None
MIC, minimum inhibitory concentration; CTX, cefotaxime; MEM, meropenem; TZP, piperacillin-tazobactam; CST, colistin.
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three patients with K. pneumoniae cleared bacteremia and were
alive at 14 days after the positive culture, but the patient with E.
coli bacteremia died from sepsis.
PCR and sequencing showed that all 4 isolates possessed the
blaOXA-48 gene whereas none had the blaNDM-1 gene. The MICs of b-
lactams reﬂected the presence or absence of ESBLs in addition to
the ertapenem non-susceptibility due to production of OXA-48
(ertapenem MICs of 1 mg/ml), as non-ESBL-producing K. pneu-
moniae c82 was susceptible to cefotaxime but the other three
isolates producing ESBL were resistant to it. The MICs of
meropenem, which all patients received for therapy, ranged
between 0.25 and 0.5 mg/ml. The low meropenem MICs were
consistent with the favorable survival rate (3 of the 4 patients),
though the number of patients was too small to make a deﬁnitive
conclusion. All isolates remained susceptible to tigecycline and
colistin.
By MLST, the isolates belonged to distinct clonal lineages. The
E. coli isolate had a novel allelic proﬁle ST4144, which represented
a single locus variant (SLV) of ST38 which is commonly associated
with OXA-48 production in Europe and the Middle East including
Egypt and Lebanon.5 The K. pneumoniae isolates belonged to
ST340, 1425 and 29. ST340 is a SLV of ST258 and frequently
associated with production of various carbapenemases including
KPC.6–8 ST29 had previously been reported for an OXA-48-
producing isolate from Kuwait,5 whereas ST1425 was a novel
allelic proﬁle.
We then screened the genetic environment of blaOXA-48 by PCR
mapping using E. coli TOP10 transformants harboring the blaOXA-
48-carrying plasmids and custom primers based on published
sequences.9 A copy of IS1999 was present upstream of blaOXA-48 in
all 4 isolates. However, IS1999 was intact in two isolates and
interrupted by IS1R in the other two isolates. lysR was identiﬁed
downstream of blaOXA-48, without interruption by an IS element.
These ﬁndings were overall in agreement with a previous study
reporting the genetic support of blaOXA-48.
9
In summary, our study estimated the prevalence of blaOXA-48 at
approximately 4% and less than 1% among ESBL-producing and
non-ESBL-producing E. coli and K. pneumoniae causing bacteremia,
respectively, at the largest tertiary hospital in Abu Dhabi. However,the polyclonality of the isolates observed here is concerning for
ongoing horizontal and regional spread of blaOXA-48.
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